Transition Therapeutics, Inc. (TTHI)

Oncology Corporate Profile

Stock Performance

0.8450
-0.0050

HQ Location

101 College Street, Suite 220
Toronto, Ontario, Canada M5G 1L7

Company Description

Transition is a biopharmaceutical development company, advancing novel therapeutics for CNS and metabolic disease indications. The Company's wholly-owned subsidiary, Transition Therapeutics Ireland Limited is developing CNS drug candidate ELND005 for the treatment of Alzheimer's disease and Down syndrome.

Website: http://www.transitiontherapeutics.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
TT701androgen receptor modulatorProstate cancerI

View additional information on product candidates here »

Source: http://www.transitiontherapeutics.com

Recent News Headlines

8/21/2017 06:23 am

8/21/2017 06:23 am

5/14/2017 12:19 pm

OPKO Health Completes Acquisition of Transition Therapeutics

8/31/2016 05:00 am

[Business Wire] - OPKO Health, Inc. , announces that it has completed its previously announced acquisition of Transition Therapeutics, Inc. , by way of a plan of arrangement which was approved by Transition Therapeutics’ shareholders at their meeting held on August 25, 2016.

Transition Therapeutics Shareholders Approve Acquisition by OPKO Health

8/26/2016 12:05 pm

[Business Wire] - OPKO Health, Inc. , announces that at a Special Shareholder Meeting held on August 25, 2016 shareholders of Transition Therapeutics, Inc. holding approximately 93% of the outstanding common shares, voted to approve the previously announced agreement under which OPKO Health will acquire Transition Therapeutics.

Transition Therapeutics Announces Special Shareholder Meeting Voting Results Including Shareholder Approval of the Plan of Arrangement with OPKO Health, Inc.

8/25/2016 10:04 pm

[PR Newswire] - TORONTO, Aug. 25, 2016 /PRNewswire/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) is pleased to announce that the Company has received shareholder approval for the previously announced plan of arrangement involving Transition, OPKO Health, Inc., OPKO Global Holdings, Inc. and the Transition Shareholders (the "Arrangement"). A total of 24,586,901 common shares, approximately 63.4% of the outstanding common shares, were represented at the meeting of Transition Shareholders (the "Meeting") in person or by proxy. The Arrangement was approved by shareholders holding approximately 92.9% of the common shares of Transition who voted on the Arrangement in person or by proxy at the Meeting.

Transition Therapeutics Announces Special Shareholder Meeting Voting Results Including Shareholder Approval of the Plan of Arrangement with OPKO Health, Inc.

8/25/2016 10:04 pm

[CNW Group] - Transition Therapeutics Announces Special Shareholder Meeting Voting Results Including Shareholder Approval of the Plan of Arrangement with OPKO Health, Inc.

OPKO Health to Acquire Transition Therapeutics

6/30/2016 06:00 am

[Business Wire] - OPKO Health, Inc. and Transition Therapeutics Inc. announce the signing of a definitive agreement under which OPKO will acquire Transition Therapeutics, a clinical stage biotechnology company.

Transition Therapeutics Receives Notification From NASDAQ

6/3/2016 10:00 am

[PR Newswire] - TORONTO, June 3, 2016 /PRNewswire/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) today announced that it received written notification from the NASDAQ Stock Market ("NASDAQ") on May 31, 2016 advising the Company that because the bid price of the Company's common shares for the previous 30 consecutive trading days had closed below the minimum $1.00 per share (the "Minimum Price Requirement") required for continued listing on the NASDAQ Global Market, the Company is not in compliance with NASDAQ Listing Rule 5450(a)(1). The notification letter has no effect on the listing of the Company's common shares at this time.

Transition Therapeutics Receives Notification From NASDAQ

6/3/2016 10:00 am

[CNW Group] - Transition Therapeutics Receives Notification From NASDAQ

The Center for Cancer and Blood Disorders Selects Flatiron Health OncoEMR® to Support Its Transition to Value-Based Care

5/18/2016 05:52 pm

(Flatiron Health) May 18, 2016 — Flatiron Health announced today that The Center for Cancer and Blood Disorders (CCBD), a comprehensive community oncology practice with nine locations in the Fort Worth, Texas region, selected OncoEMR® as their medical oncology electronic health record solution to support long-term value-based care initiatives and meet the practice’s evolving technology needs.

Transition Therapeutics Announces Third Quarter Fiscal 2016 Financial Results

5/11/2016 08:00 pm

[CNW Group] - Transition Therapeutics Announces Third Quarter Fiscal 2016 Financial Results

Transition Therapeutics Announces Third Quarter Fiscal 2016 Financial Results

5/11/2016 08:00 pm

[PR Newswire] - TORONTO, May 11, 2016 /PRNewswire/ - Transition Therapeutics Inc. ("Transition" or the "Company") (TSX: TTH; NASDAQ: TTHI), a biopharmaceutical development company advancing novel ...

Transition Therapeutics to Hold Conference Call on Third Quarter Fiscal 2016 Financial Results on Wednesday, May 11th, at 4:30 P.M. EST

5/9/2016 08:00 pm

[CNW Group] - Transition Therapeutics to Hold Conference Call on Third Quarter Fiscal 2016 Financial Results on Wednesday, May 11th, at 4:30 P.M. EST

Transition Therapeutics to Hold Conference Call on Third Quarter Fiscal 2016 Financial Results on Wednesday, May 11th, at 4:30 P.M. EST

5/9/2016 08:00 pm

[PR Newswire] - TORONTO, May 9, 2016 /PRNewswire/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) will hold a conference call on Wednesday, May 11th, 2016 at 4:30 P.M. EST to discuss Third Quarter Fiscal 2016 financial results. Dr. Tony Cruz, Chairman and Chief Executive Officer of the Company, will host the call. Transition will announce its financial results for this period in a press release to be issued prior to the call. In order to participate in the conference call, please call (800) 698-9012 (North America) and (303) 223-4374 (International). A webcast is also available at www.transitiontherapeutics.com A replay of the conference call will be available on Transition's website for seven days following the call. Transition is a biopharmaceutical development company, advancing novel therapeutics for CNS, metabolic diseases and androgen deficiency indications.

American Society of Hematology Presents Toolkit to Support Quality of Care in the Transition from Pediatric to Adult Practices

5/6/2016 04:51 pm

(ASH) May 5, 2016 - The American Society of Hematology (ASH) today presented tools to help hematologists ensure quality care for their patients who are transitioning from pediatric to adult practices.

Transition Therapeutics Announces Dosing of First Patient in Phase 2 Study of Drug Candidate TT701

4/25/2016 08:00 pm

[CNW Group] - Transition Therapeutics Announces Dosing of First Patient in Phase 2 Study of Drug Candidate TT701